PIONEERING FIRST-IN-CLASS ANTAGONISTS OF THE RETINOID NUCLEAR RECEPTOR PATHWAY FOR UNMET MEDICAL NEEDS
Kayothera specializes in inhibiting two of the last remaining nuclear receptors pathways to be drugged – the retinoid and rexinoid nuclear receptors. These pathways are clinically validated to drive adverse cardiometabolic and cancer outcomes, yet have no available inhibitors – until now.
Kayothera’s unique approach blocks the formation of the retinoid or rexinoid nuclear ligands with novel, orally-available small molecules that have proven to be safe and effective therapies. We are developing these medicines to provide patients with new options for managing diabetes, obesity and additional unmet medical needs.
LATEST NEWS
KayoThera to graduate from Endless Frontier Labs Accelerator
KayoThera has taken part in the NYU Stern Business School Endless Frontier Labs accelerator program since October 2020 to refine the business plan and expand the company trajectory and growth initiatives. This accelerator was exceptionally valuable to the development...
KayoThera founders publish Nature Cancer review on new therapeutic strategies to treat incurable cancers
Announcing a new review on emerging strategies to treat advanced cancers published in Nature Cancer.
KayoThera founders announce discovery of a new organelle driving cancer metastasis
In the cover article of the March issue of Nature Cell Biology, Dr. Mark Esposito and Dr. Yibin Kang announce the discovery of a novel driver of breast and prostate cancer metastasis. This newly discovered organelle is driven by a relatively unknown protein named...
KayoThera will present at BioNJ’s 10th Annual Biopartnering conference
KayoThera will be presenting at this year's 10th Annual BioNJ Biopartnering Conference. Please join us Tuesday, October 6 & Wednesday, October 7, 2020.
KayoThera launches with Seed Funding Round from NJHF
Kayothera, an early-stage therapeutics company and Princeton University spinout, is working to give hope to some of the most vulnerable cancer patients. Now the company’s aspirations are being bolstered by significant seed funding received from the New Jersey Health...